Advertisement Nanosphere closes IPO - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Nanosphere closes IPO

Molecular diagnostics firm Nanosphere said that the underwriters of its recent initial public offering have exercised their over-allotment option in full to purchase an additional 1.05 million shares of Nanosphere's common stock at $14.00 per share, less underwriting discounts and commissions.

The option was granted in connection with Nanosphere’s initial public offering of 7,000,000 shares. The closing of the sale of all 8,050,000 shares by Nanosphere to the underwriters occurred earlier today.

Credit Suisse Securities (USA) acted as the sole book-runner for the offering. Piper Jaffray & Co, Leerink Swann, and Allen & Company acted as co-managers.